title: Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.
abstract: Amoxicillin is considered an option for postexposure prophylaxis of Bacillus anthracis in pregnant and postpartum women who are breastfeeding and in children because of the potential toxicities of ciprofloxacin and doxycycline to the fetus and child. The amoxicillin regimen that effectively kills B. anthracis and prevents resistance is unknown. Fourteen-day dose range and dose fractionation studies were conducted in in vitro pharmacodynamic models to identify the exposure intensity and pharmacodynamic index of amoxicillin that are linked with optimized killing of B. anthracis and resistance prevention. Studies with dicloxacillin, a drug resistant to B. anthracis beta-lactamase, evaluated the role of beta-lactamase production in the pharmacodynamic indices for B. anthracis killing and resistance prevention. Dose fractionation studies showed that trough/MIC and not time above MIC was the index for amoxicillin that was linked to successful outcome through resistance prevention. Failure of amoxicillin regimens was due to inducible or stable high level expression of beta-lactamases. Studies with dicloxacillin demonstrated that a time above MIC of ≥94% was linked with treatment success when B. anthracis beta-lactamase activity was negated. Recursive partitioning analysis showed that amoxicillin regimens that produced peak concentrations of <10.99 μg/ml and troughs of >1.75 μg/ml provided a 100% success rate. Other amoxicillin peak and trough values produced success rates of 28 to 67%. For postpartum and pregnant women and children, Monte Carlo simulations predicted success rates for amoxicillin at 1 g every 8 h (q8h) of 53, 33, and 44% (30 mg/kg q8h), respectively. We conclude that amoxicillin is suboptimal for postexposure prophylaxis of B. anthracis in pregnant and postpartum women and in children.
authors.affiliation: Institute for Therapeutic Innovation, University of Florida College of Medicine, Orlando, Florida, USA.
authors.forename: Arnold
authors.initials: A
authors.lastname: Louie
authors.forename: Brian
authors.initials: B
authors.lastname: Vanscoy
authors.forename: Weiguo
authors.initials: W
authors.lastname: Liu
authors.forename: Robert
authors.initials: R
authors.lastname: Kulawy
authors.forename: G L
authors.initials: GL
authors.lastname: Drusano
mesh_terms: D000658:Amoxicillin / Q000493:pharmacokinetics* / Q000494:pharmacology; D000881:Anthrax / Q000382:microbiology / Q000517:prevention & control; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001408:Bacillus anthracis / Q000187:drug effects* / Q000254:growth & development; D002648:Child; D015169:Colony Count, Microbial; D003198:Computer Simulation; D004009:Dicloxacillin / Q000493:pharmacokinetics* / Q000494:pharmacology; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D005260:Female; D015870:Gene Expression; D006207:Half-Life; D006801:Humans; D008826:Microbial Sensitivity Tests; D015233:Models, Statistical; D009010:Monte Carlo Method; D011247:Pregnancy; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000658:Amoxicillin; D004009:Dicloxacillin; D001618:beta-Lactamases
references.citation: Science. 1994 Nov 18;266(5188):1202-8
references.pmid: 7973702
references.citation: Eur J Clin Pharmacol. 1992;43(3):283-8
references.pmid: 1425893
references.citation: Ital J Biochem. 1977 Jan-Feb;26(1):37-43
references.pmid: 405348
references.citation: Curr Opin Obstet Gynecol. 1994 Feb;6(1):50-7
references.pmid: 8180351
references.citation: Eur J Biochem. 1976 Feb 2;62(1):95-101
references.pmid: 814004
references.citation: MMWR Recomm Rep. 2010 Jul 23;59(RR-6):1-30
references.pmid: 20651644
references.citation: Clin Pediatr (Phila). 2007 Mar;46(2):121-6
references.pmid: 17325084
references.citation: Antimicrob Agents Chemother. 2012 Jan;56(1):513-7
references.pmid: 22064542
references.citation: Emerg Infect Dis. 2006 Nov;12(11):1631-7
references.pmid: 17283610
references.citation: Antimicrob Agents Chemother. 2008 Jul;52(7):2486-96
references.pmid: 18458134
references.citation: Am J Obstet Gynecol. 2008 Jan;198(1):108.e1-6
references.pmid: 18061131
references.citation: JAMA. 2002 May 1;287(17):2236-52
references.pmid: 11980524
references.citation: J Clin Microbiol. 2002 Jun;40(6):1902-7
references.pmid: 12037041
references.citation: Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96
references.pmid: 7587056
references.citation: Pediatr Infect Dis J. 1998 May;17(5):429-31
references.pmid: 9613662
references.citation: Antimicrob Agents Chemother. 2005 Dec;49(12):4920-7
references.pmid: 16304153
references.citation: Clin Pharmacol Ther. 2007 Apr;81(4):547-56
references.pmid: 17329990
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):822-30
references.pmid: 21115791
references.citation: Infect Dis Clin North Am. 1995 Sep;9(3):639-51
references.pmid: 7490437
references.citation: Paediatr Drugs. 2008;10(5):329-35
references.pmid: 18754699
references.citation: Antimicrob Agents Chemother. 2005 Dec;49(12):5099-106
references.pmid: 16304178
references.citation: Antimicrob Agents Chemother. 2007 Apr;51(4):1373-9
references.pmid: 17296745
references.citation: Obstet Gynecol. 1993 Jun;81(6):919-21
references.pmid: 8497356
references.citation: Clin Pharmacol Ther. 1985 Sep;38(3):241-50
references.pmid: 4028617
references.citation: Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
references.pmid: 9455502
references.citation: J Fam Pract. 2001 May;50(5):457-9, 463-5
references.pmid: 11350712
references.citation: Am J Obstet Gynecol. 1993 Feb;168(2):667-73
references.pmid: 8438948
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1229-39
references.pmid: 22155821